SC
TGTX icon

SummitTX Capital’s TG Therapeutics TGTX Stock Holding History

SummitTX Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339K Sell
10,217
-32,875
-76% -$980K 0.01% 630
2025
Q4 		$1.28M Buy
43,092
+28,523
+196% +$932K 0.04% 372
2025
Q3 		$526K Buy
+14,569
New +$480K 0.02% 517

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SummitTX Capital's TGTX Position: Q1 2026 in Review

SummitTX Capital reduced its TG Therapeutics (TGTX) stake by 76% in Q1 2026, selling an estimated $980K and leaving 10,217 shares worth $339K. The position accounts for 0.01% of the portfolio, ranked #630.

SummitTX Capital first reported a position in TGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.28M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • SummitTX Capital held 10,217 shares of TG Therapeutics worth $339K as of Q1 2026.
  • SummitTX Capital sold 32,875 TG Therapeutics shares in Q1 2026, an estimated $980K.
  • TG Therapeutics made up 0.01% of SummitTX Capital's portfolio in Q1 2026, its #630 holding.
  • SummitTX Capital first reported a position in TG Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • SummitTX Capital's TG Therapeutics position peaked at $1.28M in Q4 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.